Abstract
In the present issue of the European Respiratory Journal, Lavelle et al. 2 from Dublin, Ireland report on two perturbing cases of severe liver toxicity that developed 3 and 4 months, respectively, after sitaxentan therapy had been initiated. These patients showed severe liver dysfunction, with markedly elevated bilirubin levels >300 μmol·L−1 and elevated prothrombin times. In both patients, liver biopsies showed extensive hepatocellular damage and infiltrates of eosinophils and lymphocytes. As in the first case, liver function deteriorated for several weeks after discontinuation of sitaxentan. Corticosteroid therapy was not attempted. One of these patients recovered slowly, the other, however, died from pneumonia ∼2 months after withdrawal of sitaxentan. At that time, bilirubin levels were still >200 μmol·L−1, indicating persistent liver dysfunction, which may have contributed to the fatal outcome.

This publication has 9 references indexed in Scilit: